Revolutionizing Neurological Disease Treatment with a Dual Approach to Gene Therapy
Addressing the Root Cause of Proteinopathies
Neurological disorders often arise from proteinopathies, characterized by the accumulation of misfolded proteins in the brain. These misfolded proteins disrupt cellular processes, leading to neuronal death and the progressive decline in cognitive and motor functions. Canary’s dual-combination therapy targets the root cause of proteinopathies by employing two distinct yet synergistic mechanisms:
1. Vectorized Antibodies:
Our proprietary vectorized antibodies are designed to specifically bind and neutralize misfolded proteins, preventing their aggregation and toxicity. These antibodies are engineered to cross the blood-brain barrier, ensuring effective delivery to the affected areas of the brain.
2. Functional Transgene Replacement:
We utilize gene therapy to replace defective genes with functional copies, correcting the genetic abnormalities that underlie protein misfolding. This approach restores the production of normal proteins, halting the progression of disease and promoting cellular repair.
AntiMirs are short RNA molecules that are designed to bind to and inhibit the function of miRNAs. They can be used to treat diseases that are caused by the overexpression of miRNAs.
AntiMirs can be delivered to cells in a variety of ways, including
Intravenous injectionThis is the most common method of delivering AntiMirs
Intramuscular injection This method is used when the target cells are located in the muscle tissue
Intranasal delivery This method is used to deliver AntiMirs to the cells in the nose and throat
Inhalation This method is used to deliver AntiMirs to the lungs
Topical delivery This method is used to deliver AntiMirs to the skin
Canary's AlloMir gene-silencing platform can be leveraged to investigate a variety of diseases and conditions
AntiMirs are more stable than siRNAs. This is because they are single-stranded RNA molecules, while siRNAs are double-stranded RNA molecules. Double-stranded RNA molecules are more easily degraded by enzymes in the bloodstream and tissues.
AntiMirs can be designed to be more specific than siRNAs. This is because they can be designed to bind to a specific miRNA, while siRNAs can bind to a range of miRNAs.
AntiMirs may be safer than siRNAs. This is because they are less likely to trigger an immune response.
AntimicroRNA (AntiMir) therapeutics have several potential advantages over siRNA therapeutics:
Our mission is to harness the transformative power of gene therapy and AI-driven precision diagnostics to revolutionize healthcare and empower individuals to live healthier, longer lives. We are pioneering a novel approach to vectorized gene therapy with the aim of providing a single-dose comprehensive and lasting solution to diseases and conditions that currently have few options.
Disclaimer: Canary Global Inc.’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized